Cancers (Jun 2023)

CAR-NK Cells Targeting HER1 (EGFR) Show Efficient Anti-Tumor Activity against Head and Neck Squamous Cell Carcinoma (HNSCC)

  • Juliette Nowak,
  • Marco Bentele,
  • Ivana Kutle,
  • Katharina Zimmermann,
  • Jonathan Lukas Lühmann,
  • Doris Steinemann,
  • Stephan Kloess,
  • Ulrike Koehl,
  • Willi Roßberg,
  • Amed Ahmed,
  • Dirk Schaudien,
  • Lavinia Neubert,
  • Jan-Christopher Kamp,
  • Mark P. Kuehnel,
  • Athanasia Warnecke,
  • Axel Schambach,
  • Michael Morgan

DOI
https://doi.org/10.3390/cancers15123169
Journal volume & issue
Vol. 15, no. 12
p. 3169

Abstract

Read online

(1) Background: HNSCC is a highly heterogeneous and relapse-prone form of cancer. We aimed to expand the immunological tool kit against HNSCC by conducting a functional screen to generate chimeric antigen receptor (CAR)-NK-92 cells that target HER1/epidermal growth factor receptor (EGFR). (2) Methods: Selected CAR-NK-92 cell candidates were tested for enhanced reduction of target cells, CD107a expression and IFNγ secretion in different co-culture models. For representative HNSCC models, patient-derived primary HNSCC (pHNSCC) cell lines were generated by employing an EpCAM-sorting approach to eliminate the high percentage of non-malignant cells found. (3) Results: 2D and 3D spheroid co-culture experiments showed that anti-HER1 CAR-NK-92 cells effectively eliminated SCC cell lines and primary HNSCC (pHNSCC) cells. Co-culture of tumor models with anti-HER1 CAR-NK-92 cells led to enhanced degranulation and IFNγ secretion of NK-92 cells and apoptosis of target cells. Furthermore, remaining pHNSCC cells showed upregulated expression of putative cancer stem cell marker CD44v6. (4) Conclusions: These results highlight the promising potential of CAR-NK cell therapy in HNSCC and the likely necessity to target multiple tumor-associated antigens to reduce currently high relapse rates.

Keywords